Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -178.29% is 97% above its 5-year average of -5849.84%, near the high end of its 5-year range (-5433300.00%–187105.26%).
99.81% above its 12-month average of -91898.64%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1981.91%.
EBITDA MARGIN
-178.29%
EBITDA MARGIN AVG TTM
-91898.64%
EBITDA MARGIN AVG 3Y
-146652.37%
EBITDA MARGIN AVG 5Y
-5849.84%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.81%
CURRENT VS 3Y AVG
+99.88%
CURRENT VS 5Y AVG
+96.95%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
4D Molecular Therapeutics, Inc.
Market Cap
$675.41M
EBITDA Margin
-178.29%
TTM Avg
-91898.64%
3Y Avg
-146652.37%
5Y Avg
-5849.84%
Market Cap
$669.83M
EBITDA Margin
18.82%
TTM Avg
18.71%
3Y Avg
11.51%
5Y Avg
4.96%
Market Cap
$685.54M
EBITDA Margin
-30265.74%
TTM Avg
-30265.74%
3Y Avg
-29547.55%
5Y Avg
-23057.25%
Market Cap
$698.13M
EBITDA Margin
-4821.38%
TTM Avg
-3832.53%
3Y Avg
-2582.73%
5Y Avg
-1806.92%
Market Cap
$642.95M
EBITDA Margin
-266.60%
TTM Avg
-229.77%
3Y Avg
-154.97%
5Y Avg
-121.91%
Market Cap
$712.76M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $675.41M | -178.29% | -91898.64% | -146652.37% | -5849.84% |
| MiMedx Group, Inc. (MDXG)vs › | $669.83M | 18.82% | 18.71% | 11.51% | 4.96% |
| Annexon, Inc. (ANNX)vs › | $684.04M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $685.54M | -30265.74% | -30265.74% | -29547.55% | -23057.25% |
| Anteris Technologies Global Corp. (AVR)vs › | $698.13M | -4821.38% | -3832.53% | -2582.73% | -1806.92% |
| OmniAb, Inc. (OABI)vs › | $642.95M | -266.60% | -229.77% | -154.97% | -121.91% |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $637.34M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $712.76M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $719.02M | 52.93% | 53.31% | 49.89% | 44.80% |
Gross Margin
91.0%
EBITDA Margin
-178.3%
Operating Margin
-187.2%
Net Margin
-194.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1981.91% |
| 2026-03-31 | -2348.70% |
| 2025-12-31 | 19.62% |
| 2025-09-30 | -66582.22% |
| 2025-06-30 | -388600.00% |
| 2025-03-31 | -370478.57% |
| 2024-12-31 | -5433300.00% |
| 2024-09-30 | -1647633.33% |
| 2024-06-30 | -825240.00% |
| 2024-03-31 | -132010.71% |
| 2023-12-31 | 187105.26% |
| 2023-09-30 | -64.24% |
| 2023-06-30 | -12994.56% |
| 2023-03-31 | -9757.38% |
| 2022-12-31 | -2221.81% |
| 2022-09-30 | -5195.60% |
| 2022-06-30 | -17259.26% |
| 2022-03-31 | -2131.75% |
| 2021-12-31 | -26493.48% |
| 2021-09-30 | -1631.11% |
| 2021-06-30 | -49.56% |
| 2021-03-31 | -796.45% |
| 2020-12-31 | 2052.30% |
| 2020-09-30 | -100.35% |
| 2020-06-30 | -407.10% |
| 2020-03-31 | -365.86% |
| 2019-12-31 | -786.70% |
| 2019-09-30 | -3100.56% |
| 2019-06-30 | -386.03% |
| 2019-03-31 | -386.03% |
| 2018-12-31 | -51.94% |
| 2018-09-30 | -51.94% |
| 2018-06-30 | -98.56% |
| 2018-03-31 | -98.56% |
